These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27221807)

  • 1. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
    Sato H; Hirakawa A; Hamada C
    Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.
    Cunanan KM; Koopmeiners JS
    Contemp Clin Trials; 2018 Aug; 71():162-172. PubMed ID: 29936124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage dose finding for cytostatic agents in phase I oncology trials.
    Yin G; Zheng S; Xu J
    Stat Med; 2013 Feb; 32(4):644-60. PubMed ID: 22855354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
    Yan D; Wages NA; Dressler EV
    J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive dose modification for phase I clinical trials.
    Chu Y; Pan H; Yuan Y
    Stat Med; 2016 Sep; 35(20):3497-508. PubMed ID: 27027650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-finding approach for genomic patterns in phase I trials.
    Kaneko S; Hirakawa A; Kakurai Y; Hamada C
    J Biopharm Stat; 2020 Sep; 30(5):834-853. PubMed ID: 32310707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.
    Cai C; Yuan Y; Ji Y
    J R Stat Soc Ser C Appl Stat; 2014 Jan; 63(1):159-173. PubMed ID: 24511160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II adaptive design for drug combination oncology trials.
    Wages NA; Conaway MR
    Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.
    Colin P; Delattre M; Minini P; Micallef S
    J Biopharm Stat; 2017; 27(6):1054-1072. PubMed ID: 28375746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.